Trial Information - Phase I/II
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Protocol ID: SGN22E-002
Sponsor: Seagen, Inc.
Status: COHORT CLOSED
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
